Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine …
JP Baak, TH Van Heijningen - Clinical cancer research: an official journal of …, 1995 - AACR
Overexpression of P-glycoprotein (Pgp) or MDR1 mRNA has been shown to be a negative
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
[引用][C] Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine …
GJ SCHUURHUIS - Clin. Cancer Res., 1995 - cir.nii.ac.jp
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1
and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response …
and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response …
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine …
GJ Schuurhuis, HJ Broxterman… - … Cancer Research: an …, 1995 - europepmc.org
Overexpression of P-glycoprotein (Pgp) or MDR1 mRNA has been shown to be a negative
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity …
GJ Schuurhuis, HJ Broxterman… - Clinical Cancer …, 1995 - pure.johnshopkins.edu
Overexpression of P-glycoprotein (Pgp) or MDR1 mRNA has been shown to be a negative
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine …
GJ Schuurhuis, HJ Broxterman… - … : an official journal …, 1995 - pubmed.ncbi.nlm.nih.gov
Overexpression of P-glycoprotein (Pgp) or MDR1 mRNA has been shown to be a negative
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
prognostic factor for clinical outcome in acute myeloid leukemia (AML). However, resistance …
[引用][C] Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine …
GJ SCHUURHUIS, HJ BROXTERMAN… - Clinical cancer …, 1995 - pascal-francis.inist.fr
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1
and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical …
and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical …
[引用][C] Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine …
S GJ - Clin Cancer Res, 1995 - cir.nii.ac.jp
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1
and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical …
and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical …